Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Leerink Partners Raises Price Target on Regeneron (REGN) Following 1Q Report
May 6, 2016 9:08 AM EDTLeerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00), following the company's 1Q earnings report. Total revenue beat consensus by 2% driven by higher collaboration revenue, and revenue grew by 38% compared to Q1 2015 and by 9% QoQ. The companys earnings fell short of consensus based on higher than expected SG&A and taxes. Pro forma EPS was $2.57 below consensus of $2.68.
Analyst Geoffrey Porges... More
Regeneron (REGN) Misses Q1 EPS by 1c; Reaffirms
May 5, 2016 6:36 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $2.57, $0.01 worse than the analyst estimate of $2.58. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.18 billion.
"The year is off to a very productive start at Regeneron. This quarter, we saw continued strong sales growth with EYLEA, made additional... More
Trading Radar for 5/5: Alibaba (BABA), GoPro (GPRO), Herbalife (HLF), Wynn Resorts (WYNN), Activision (ATVI) Report
May 4, 2016 2:39 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
3D Systems (NYSE: DDD) - consensus EPS $0.05
AAC Holdings (NYSE: AAC) - consensus EPS $0.15
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus loss $0.08
Agios Pharma (Nasdaq: AGIO) - consensus loss $0.79
Alibaba (NYSE: BABA) - consensus EPS... More
Sanofi sees 'strong strategic' fit with U.S. Medivation
May 4, 2016 10:39 AM EDTPARIS (Reuters) - Sanofi sees a strong strategic fit with Medivation (NASDAQ: MDVN) even though its tie-up proposal was rejected by the U.S. cancer drug maker last week, the company's chief executive said on Wednesday.
The French drugmaker went public with a $9.3 billion proposal to buy Medivation on April 28 but the target said offer undervalued the company and its pipeline of drugs.
... MoreBig pharma dominates ranking of stocks with best five-year returns
May 3, 2016 10:24 AM EDTBy Laila Kearney
NEW YORK (Reuters) - U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year returns, according to an analysis released on Tuesday by Boston Consulting Group.
Drug company Regeneron Pharmaceuticals (NASDAQ: REGN), which had an average annual total share return of 75.3 percent, was the top performer. Allergan (NYSE: AGN) and Gilead Sciences (NASDAQ: GILD), with 43.3 percent and 41.4 percent average annual returns, respectively, took second and third... More
